The Novo Nordisk Foundation has committed DKK 950 million (EUR 127 million) to establish the Novo Nordisk Foundation Cellerator, a world-class facility aimed at advancing cell therapies for chronic diseases like heart failure, Parkinson’s, kidney disease, type 1 diabetes, and several forms of cancer. This facility will be located at the Technical University of Denmark (DTU) in Lyngby and is expected to be operational by 2027.
The Cellerator will serve as a crucial link in Denmark’s cell therapy ecosystem, focusing on the final development steps and upscaling of cell therapies for human testing, addressing a critical gap in translating laboratory breakthroughs into real-world treatments.
It will cater to public and private, national, and international clients, including academia, biotech, and the pharmaceutical industry, providing a range of services from process development to product GMP manufacturing, product release, and regulatory support.
Thomas H.R. Carlsen, CEO of the Novo Nordisk Foundation Cellerator, emphasized the transformative potential of cell therapies in treating or even curing chronic diseases with a one-off procedure, moving beyond merely managing symptoms.
The facility will support various cell therapy types, including those derived from embryonic stem cells, induced pluripotent stem cells, and adult stem cells, and will have built-in flexibility to adapt to the rapidly evolving field.
The Cellerator will be the first large-scale production site in Denmark, gathering a broad range of expertise and services under one roof, and is positioned to become a leading player in Europe and a model for similar facilities globally.
The Novo Nordisk Foundation is forming partnerships with entities like reNEW, a research consortium, and is in dialogue with stakeholders across the Danish cell therapy landscape and internationally, aiming to enable groundbreaking stem cell discoveries to reach proof-of-concept in human chronic disease trials.
1. Potential to Revolutionize Treatment:
The establishment of the Cellerator signifies a monumental step in medical science, potentially revolutionizing the treatment of chronic diseases. It raises the question of how quickly these advanced therapies can be made accessible to the global population and what impact they will have on the overall quality of life and life expectancy.
2. Collaboration and Co-Creation:
The emphasis on co-creation and collaboration with various stakeholders, including academic, clinical, and biotech scientists, is noteworthy. It prompts reflection on how such collaborative approaches can accelerate the development and deployment of innovative therapies and how they can be replicated in other fields of research and development.
3. Global Impact and Leadership:
With ambitions to be a leading player in Europe and a model globally, the Cellerator is poised to position Denmark as a leader in cell therapy research and application. It invites contemplation on how this leadership can influence global standards and practices in cell therapy and how it can foster international cooperation in the pursuit of cures for chronic diseases.
Find out more about the Novo Nordisk Foundation here.